|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||392.80 - 393.00|
|52-week range||341.00 - 473.65|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||23.32|
|Forward dividend & yield||9.97 (2.54%)|
|Ex-dividend date||17 Mar 2022|
|1y target est||N/A|
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
As the leader in medical diagnostics, Roche (OTC: RHHB.F) acted quickly to deliver valuable COVID-19 screening tests to the marketplace. Assisted by COVID-related sales, its diagnostics division is now delivering stronger growth than its larger pharmaceuticals division. Roche's medical diagnostics division saw strong growth throughout 2021 and into the begining of 2022.